7 published verifications about New Zealand New Zealand ×
“Only two of seven triptan medicines available globally are publicly funded in New Zealand: sumatriptan and rizatriptan.”
Current New Zealand evidence supports the claim. PHARMAC’s schedule and decision records show that only sumatriptan and rizatriptan are publicly funded, while the other five triptan medicines used globally are not subsidised in New Zealand. Older sources about availability or approval do not rebut this, because they address access rather than public funding.
“In New Zealand, funded sumatriptan and funded rizatriptan are available at the standard prescription co-payment of about NZ$5 for people with a Community Services Card.”
The evidence supports that funded sumatriptan and funded rizatriptan are available in New Zealand, but it does not support the claim that people with a Community Services Card pay about NZ$5 for them. Official sources describe CSC prescription charges as reduced, and sometimes zero, relative to the usual standard charge. That makes the CSC-specific pricing in the claim inaccurately framed.
“A recommended initial course of 6–10 sessions at clinics in Auckland, New Zealand typically totals NZ$480–NZ$1,400 before any maintenance sessions.”
The stated NZ$480–NZ$1,400 range fits some lower-cost clinic services, but it is not a reliable typical total across Auckland clinics as a whole. For common private mental-health services, posted fees often imply 6–10 sessions costing about NZ$1,140–NZ$2,600, well above the claimed ceiling. Because the claim does not specify the treatment type, it gives an overly low impression of what many patients would actually pay.
“Sessions at clinics in Auckland, New Zealand, typically cost NZ$80–NZ$140 each.”
NZ$80–NZ$140 is a common price band for some Auckland clinic services, but not for clinic sessions overall. Many enrolled GP visits are often below NZ$80, especially at subsidised or VLCA practices, while some private therapy sessions are above NZ$140. Without specifying casual, unsubsidised, urgent-care, or allied-health visits, the range is too broad to describe what Auckland clinic sessions typically cost.
“In New Zealand, having fewer than 9 deceased organ donors per million people results in hundreds of patients dying each year while waiting for organ transplants.”
The claim is not supported by current New Zealand evidence. Recent official and medical sources place deceased donor rates above 9 per million in many recent years, and the available waiting-list mortality figures are far below “hundreds each year.” Patients do die waiting for transplants, but this claim overstates both the donor-rate problem and the scale of deaths.
“In 2011, there were 400 people on the transplant waiting list in New Zealand.”
The claim is directionally accurate but not exact. The strongest official evidence puts New Zealand’s organ transplant waiting list at 420 people on 31 December 2011, while other sources describe the figure more loosely as about 400 to 500. Saying “400” is a reasonable approximation, but it understates the specific official year-end count and leaves out that the list changed over time.
“Living Cell Technologies conducted clinical trials in New Zealand in which islet cells from Auckland Island pigs were transplanted into eight patients with type 1 diabetes.”
The core description is accurate, but the patient count is incomplete. Reliable sources confirm that Living Cell Technologies conducted New Zealand trials transplanting Auckland Island pig islet cells into people with type 1 diabetes. However, the strongest later evidence reports 14 patients treated overall, so “eight patients” appears to describe only an early cohort, not the full New Zealand trial program.